📰 Nasdaq Coll News
Page 3 - Nasdaq Coll News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Coll. Real-time updates on events, politics, business and more.
August 14, 2023
Gladius Capital Management LP cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 27.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,235 shares of the specialty pharmaceutical company’s stock after selling 478 shares during the […]
August 9, 2023
HC Wainwright reissued their neutral rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a report issued on Friday morning, Benzinga reports. Several other analysts have also commented on COLL. Needham & Company LLC reaffirmed a buy rating and set a $35.00 price target on shares of Collegium Pharmaceutical in a research report […]
August 8, 2023
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s share price was up 4.9% during trading on Monday . The stock traded as high as $25.02 and last traded at $24.64. Approximately 108,557 shares traded hands during trading, a decline of 73% from the average daily volume of 396,780 shares. The stock had previously closed at […]
August 7, 2023
ProVise Management Group LLC purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 30,388 shares of the specialty pharmaceutical company’s stock, valued at approximately $729,000. ProVise Management Group LLC owned about 0.09% of […]
August 5, 2023
StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a hold rating to a buy rating in a report released on Wednesday. Several other equities analysts have also commented on COLL. Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $35.00 in a report on Tuesday, April 25th. Needham & […]
August 4, 2023
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of […]
July 30, 2023
Emerald Mutual Fund Advisers Trust decreased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 1.3% in the 1st quarter, Holdings Channel reports. The firm owned 677,160 shares of the specialty pharmaceutical company’s stock after selling 8,733 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Collegium Pharmaceutical were worth $16,245,000 […]
July 27, 2023
Foundry Partners LLC acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 136,480 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,274,000. Foundry […]
July 14, 2023
StockNews.com lowered shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a buy rating to a hold rating in a research report report published on Monday morning. Several other analysts also recently weighed in on the company. Needham & Company LLC restated a buy rating and set a $35.00 target price on shares of Collegium […]
June 28, 2023
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) EVP Shirley R. Kuhlmann sold 17,984 shares of Collegium Pharmaceutical stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $21.72, for a total transaction of $390,612.48. Following the transaction, the executive vice president now directly owns 119,518 shares of the […]